Inovio Pharmaceuticals, Inc. (NASDAQ:INO) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday.

A number of other brokerages also recently weighed in on INO. Stifel Nicolaus reiterated a “buy” rating and set a $11.00 price target on shares of Inovio Pharmaceuticals in a report on Thursday, May 25th. Maxim Group set a $12.00 target price on Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, June 8th. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Inovio Pharmaceuticals in a research note on Friday, June 9th. Aegis raised their target price on Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, May 25th. Finally, Zacks Investment Research upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price for the company in a research note on Tuesday, July 11th. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. Inovio Pharmaceuticals has a consensus rating of “Buy” and an average price target of $20.78.

Inovio Pharmaceuticals (NASDAQ INO) opened at 5.49 on Friday. The company’s market capitalization is $414.00 million. The firm’s 50-day moving average price is $6.88 and its 200 day moving average price is $6.81. Inovio Pharmaceuticals has a 12-month low of $5.32 and a 12-month high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative return on equity of 65.97% and a negative net margin of 235.91%. The firm had revenue of $20.41 million during the quarter, compared to the consensus estimate of $16.29 million. During the same period last year, the business posted ($0.26) EPS. The business’s revenue was up 229.2% compared to the same quarter last year. On average, analysts expect that Inovio Pharmaceuticals will post ($0.93) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was first reported by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.watchlistnews.com/inovio-pharmaceuticals-inc-nasdaqino-rating-increased-to-sell-at-valuengine/1471511.html.

In related news, Director David B. Weiner sold 8,000 shares of the firm’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $8.00, for a total value of $64,000.00. Following the transaction, the director now owns 740,956 shares of the company’s stock, valued at approximately $5,927,648. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 10.60% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Inovio Pharmaceuticals by 7.9% in the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock valued at $20,510,000 after buying an additional 226,861 shares during the last quarter. Candriam Luxembourg S.C.A. acquired a new position in shares of Inovio Pharmaceuticals during the second quarter valued at $1,411,000. Credit Suisse AG boosted its position in shares of Inovio Pharmaceuticals by 108.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 69,068 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Inovio Pharmaceuticals by 12.5% in the first quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock valued at $3,708,000 after buying an additional 62,045 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new position in shares of Inovio Pharmaceuticals during the second quarter valued at $392,000. 22.92% of the stock is currently owned by institutional investors and hedge funds.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.